China Pharma Holdings (CPHI) Land & Improvements (2014 - 2023)

China Pharma Holdings (CPHI) has reported Land & Improvements for 10 consecutive years, with $389808.0 the latest figure, recorded in Q2 2023.

• For the quarter ending Q2 2023, Land & Improvements fell 7.12% year-over-year to $389808.0; the trailing twelve-month figure through Jun 2023 stood at $389808.0 (down 7.12% YoY), and the FY2022 full-year result was $404427.0, down 8.46% from the prior year.
• Land & Improvements fell to $389808.0 in Q2 2023 per CPHI's latest filing, from $409895.0 in the prior quarter.
• Across five years, Land & Improvements topped out at $443697.0 in Q1 2022 and bottomed at $389808.0 in Q2 2023.
• Historically, Land & Improvements has averaged $416443.1 across 5 years, with a median of $413603.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Land & Improvements climbed 9.59% in 2021, then fell 8.65% in 2022.
• Over 5 years, Land & Improvements stood at $403755.0 in 2019, then advanced by 6.92% to $431681.0 in 2020, then climbed by 2.34% to $441783.0 in 2021, then retreated by 8.46% to $404427.0 in 2022, then dropped by 3.61% to $389808.0 in 2023.
• According to Business Quant data, Land & Improvements over the past three periods registered $389808.0, $409895.0, and $404427.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.